Peter L Anderson
Overview
Explore the profile of Peter L Anderson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
247
Citations
9157
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mainella V, Branchford B, Nemkov T, Hosford S, Coyle R, Johnson B, et al.
J Antimicrob Chemother
. 2025 Mar;
PMID: 40037647
Background: Previous studies have primarily focused on nucleos(t)ide reverse transcriptase inhibitor pharmacology in peripheral blood mononuclear cells (PBMCs) and erythrocytes via dried blood spots (DBS), but not other major blood...
2.
Noguchi L, Owor M, Mgodi N, Gati Mirembe B, Dadabhai S, Horne E, et al.
Lancet HIV
. 2025 Feb;
12(3):e180-e190.
PMID: 39954697
Background: In 2021, WHO recommended dapivirine vaginal rings (DVRs) for HIV prevention, but noted evidence gaps for breastfeeding populations. This trial aimed to describe safety profiles associated with DVRs and...
3.
Ho K, Hoesley C, Anderson P, Fernandez-Romero J, Friedland B, Kelly C, et al.
J Acquir Immune Defic Syndr
. 2025 Jan;
97(4):379-386.
PMID: 39808074
Background: On demand, topical PrEP is desired by those preferring episodic, nonsystemic PrEP. PC-1005 gel (MIV-150, zinc, and carrageenan) exhibits in vitro antiviral HIV-1, human papillomavirus (HPV), and herpes simplex...
4.
Coppinger C, Anderson P
Expert Opin Drug Metab Toxicol
. 2025 Jan;
:1-4.
PMID: 39757464
No abstract available.
5.
Coppinger C, Anderson P
J Int AIDS Soc
. 2024 Nov;
27(12):e26397.
PMID: 39587904
No abstract available.
6.
van den Elshout M, Wijstma E, Boyd A, Jongen V, Coyer L, Anderson P, et al.
Ned Tijdschr Geneeskd
. 2024 Oct;
168.
PMID: 39474835
Objective: HIV can be effectively prevented by oral HIV pre-exposure prophylaxis (PrEP). When PrEP was introduced, there was apprehension that condom use would decrease and STIs would increase. The purpose...
7.
Ryan P, Odegard E, Meeds H, Lartey M, Ganu V, Tachi K, et al.
J Clin Virol
. 2024 Oct;
175:105733.
PMID: 39413542
Background: The goal of treatment of hepatitis B virus (HBV) and human immunodeficiency virus (HIV) coinfection is suppression of both viruses; yet incomplete HBV suppression on tenofovir (TFV) disoproxil fumarate...
8.
Davey D, Dadan S, Bheemraj K, Waitt C, Khoo S, Myer L, et al.
Antiviral Res
. 2024 Sep;
231:106014.
PMID: 39332538
Background: There are few data on tenofovir-diphosphate (TFV-DP) concentrations in pregnant and postpartum women on Tenofovir Disoproxil Fumarate-Emtricitabine (TDF-FTC) or Tenofovir Alafenamide-Emtricitabine (TAF-FTC). Methods: Eligible pregnant women were randomized to...
9.
Bae J, Tantawy M, Gong Y, Langaee T, Lartey M, Ganu V, et al.
Antimicrob Agents Chemother
. 2024 Jul;
68(9):e0054924.
PMID: 39078131
The nucleos(t)ide analogs require phosphorylation to the pharmacologically active anabolites in cells. We investigated the hypothesis that single-nucleotide polymorphisms (SNPs) in genes that encode transporters and phosphodiesterase (PDE) enzymes involved...
10.
Wu L, Saina M, Brown C, Chege D, Donnell D, Glidden D, et al.
Front Reprod Health
. 2024 Jun;
6:1325257.
PMID: 38860025
Background: Oral pre-exposure prophylaxis (PrEP) using co-formulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) is a potent HIV prevention method for men and women, with its efficacy highly dependent on...